Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Jul 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through September 30, 2015 . The Company has elected to satisfy its conversion obligation under the
OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Jun 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test
OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa
Jun 09, 2015
New Preclinical Data further demonstrate the safety and efficacy of MOD-5014 (FVIIa -CTP) for both Intravenous and Subcutaneous Administration MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), today announced that the company will present new data on its long-acting clotting Factor VIIa-CTP
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger
Jun 08, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday , June 11, 2015 , to discuss the previously announced entry into a merger agreement for OPKO to acquire
OPKO Health to Acquire Bio-Reference Laboratories
Jun 04, 2015
Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy Acquisition provides national sales force to accelerate adoption of OPKO's 4Kscore TM test for aggressive prostate cancer MIAMI --(BUSINESS WIRE)-- OPKO HEALTH,
OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration
May 29, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced that it has submitted a New Drug Application (NDA) for oral Rayaldee to the U.S. Food and Drug Administration (FDA). The NDA requests marketing approval for Rayaldee for the prevention and treatment of secondary
OPKO Health to Present at the Jefferies 2015 Healthcare Conference
May 27, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015 at 4:00 PM EDT in New York City . The presentation will be webcast on the OPKO Investor Relations page of the corporate
OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting
May 18, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced six important new clinical trial results pertaining to the 4Kscore® test presented at the 2015 American Urological Association (AUA) annual meeting, May 15 to May 19, 2015 , in New Orleans .
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large Community-Based Referral Cohort
May 15, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled " A Four-kallikrein Panel Predicts High -grade Cancer on Biopsy: Independent Validation in a Community Cohort " in the journal European Urology .
OPKO Announces First Quarter Operating and Financial Results
May 11, 2015
Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015 ; OPKO Received $295 million of $570 Million Total Potential Pre-Commercialization Payments Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer Rayaldee TM New
OPKO To Announce First Quarter Financial Results on May 11, 2015
May 07, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce first quarter 2015 financial results on Monday, May 11th , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business update and discuss its
CORRECTING and REPLACING OPKO To Announce First Quarter Financial Results on May 11, 2015
May 07, 2015
MIAMI --(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: OPKO TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON MAY 11, 2015 OPKO Health, Inc. (NYSE: OPK ) will announce first quarter 2015 financial results on
OPKO Health Acquires EirGen Pharma
May 05, 2015
Developer of High Potency Specialty Pharmaceutical Products Rich Pipeline of Products Products Currently on the Market in the U.S., Europe and Japan Adds Sophisticated Pharmaceutical Manufacturing Facilities in Ireland Co-Founded by Former IVAX Pharmaceuticals Executives MIAMI --(BUSINESS WIRE)--
OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test
Apr 21, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled " Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study " in the Journal of the National Cancer Institute .
Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes
Apr 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") are convertible by holders of such Notes. The Company has elected to satisfy its conversion obligation under the Notes in shares of the Company's Common
Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
Mar 27, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of additional phase 3 clinical data in a poster at the National Kidney Foundation's Spring Clinical Meetings on March 27-28th, 2015 in Dallas, Texas , that will include data for 429 patients completing up to
OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources
Mar 23, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) announced today that SciVac Ltd. ("SciVac"), an Israeli entity in which OPKO has a forty-five percent ownership interest, has entered into an agreement pursuant to which Levon Resources Ltd. (LVN.TO)(OTC:LVNVF)(LO9.F) will acquire 100% of the
OPKO Lab Receives Accreditation From College of American Pathologists
Mar 18, 2015
CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards of Excellence in Quality Laboratory Practices NASHVILLE, Tenn. & MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that the College of American Pathologists (CAP) has awarded accreditation to
Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference
Mar 06, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of late-breaking clinical data in a poster at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 6th, 2015 in San Diego, California , that will include twelve months data from OPKO's phase 3
Twelve Months Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at ENDO 2015 Conference
Mar 03, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of two posters at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 5 th , 2015 in San Diego, California , that will include twelve months data from OPKO's advanced phase 2 trial for its long
Displaying 141 - 160 of 363